Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
https://finance.yahoo.com/news/jaguar-health-licenses-fda-approved-123000496.html
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
https://finance.yahoo.com/news/jaguar-health-licenses-fda-approved-123000496.html
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
https://finance.yahoo.com/news/jaguar-health-licenses-fda-approved-123000496.html
I think you should leave him alone.
He ought to trade a portion and retain the main core for the run. With 340 million in the first hour, this momentum won't halt here. The next legs will see us breaking out above the MA200.
I have plenty of free shares. Yesterday, I bought 130k, and this morning, I purchased another 154k. This is the kind of stock where you only trade a portion and maintain a larger position for FDA approval.
04/16/24 09:38 AM ET Buy 37303 JAGX Executed @ $0.152
04/16/24 09:38 AM ET Buy 69397 JAGX Executed @ $0.152
04/16/24 09:38 AM ET Buy 33000 JAGX Executed @ $0.1512
04/16/24 09:53 AM ET Buy 666 JAGX Executed @ $0.195
04/16/24 09:53 AM ET Buy 13334 JAGX Executed @ $0.195
$JAGX remember $OCGN went for .20 cents to $16.00?
Gap filled! Wowwwwwww
I hit the jackpot this time bro. Fully loaded!
HOLD FOR THE GOLD! $$$$ WEEEEEEEE
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Tuesday, 16 April 2024 08:30 AM
ACCESSWIRE | Article Logo
Jaguar Health, Inc.
Share this Article
Share on Twitter
Share on Facebook
Share on Linkedin
Topic:
Company Update
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force
SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC ("Venture Life"), an international consumer health company focused on the global self-care market, for Venture Life's FDA-approved oral mucositis prescription product, Gelclair, for the U.S. market.
"We are very happy to have executed the in-license agreement for Gelclair - and thus to have initiated Jaguar's commercial footprint in our core focus area of cancer supportive care," said Lisa Conte, Jaguar's president and CEO. "Oral mucositis is among the most common, painful, and debilitating cancer treatment-related side effects. Gelclair is a protective gel with a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis. Unlike other products for oral mucositis, it is not a numbing agent and does not sting the mouth."
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network (NCCN) task force.1 Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy. Of the latter, 19% may end up being hospitalized, experiencing a delay in antineoplastic treatment for high-grade mucositis management, resulting in a reduction of the quality of life, a worse prognosis and an increase in patient management costs.2
"A key attribute in the management of head and neck cancer patients with Gelclair is, in my experience, to delay the onset which may decrease the severity of oral mucositis, allowing the patients to continue meeting their nutritional needs without having to go on a feeding tube, supporting their ability to withstand their 6 weeks of radiation therapy without having to go to lower doses or treatment interruptions, and to avoid the need for heavy prescription meds for oral mucositis-related pain," said Maged Ghaly, MD, a radiation oncologist at Northwell Health Cancer Institute, Monter Cancer Center.
"Gelclair is an FDA-approved prescription product and can be commercialized without any clinical development costs for Jaguar," added Conte. "We are expanding our footprint beyond HIV-related supportive care to include cancer-related supportive care, and the in-license of Gelclair is a first building block while we await the forthcoming results from our pivotal Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as unpredictable and/or chronic debilitating diarrhea and GI urgency. We live in the age targeted therapies, and thanks to these amazing drugs cancer patients are living longer - 5, 10, 20 years. Targeted therapies often lead to more severe side effects, however, and patients want to live, not just survive."
Oral mucositis can negatively affect diet, nutrition, oral hygiene, and quality of life.3 Its adverse physical, social and psychological impacts on patients are manifest and include the need for total parenteral nutrition, higher risk of systemic infections, increased use of antifungals and opioid analgesics, increased hospitalizations with longer hospital stays, social isolation and depression due to the inability to talk and eat, subsequent dose reductions, treatment interruptions and discontinuations, and as a corollary to dose reductions and treatment interruptions/discontinuations, diminished anti-tumor responses and shorter survival.1
The economic consequences are far from trivial, with the incremental cost of oral mucositis exceeding $17,000 for patients with head and neck cancer.4
Gelclair is a clinically proven, convenient, and easy to use gel that provides rapid and long-lasting pain relief and improves the ability of oral mucositis patients to eat, drink, swallow, speak and sleep. Gelclair also reduces the need to use parenteral feeding or opiate analgesics.
About Gelclair®
INDICATIONS
GELCLAIR® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.
IMPORTANT SAFETY INFORMATION
Do not use GELCLAIR if there is a known or suspected hypersensitivity to any of its ingredients.
No adverse effects have been reported in clinical trials, although postmarketing reports have included infrequent complaints of burning sensation in the mouth.
If GELCLAIR is swallowed accidentally, no adverse effects are anticipated.
If no improvement is seen within 7 days, a physician should be consulted.
You are encouraged to report negative side effects of prescription medical products to the FDA.
Visit www.fda.gov/safety/medwatch, call 1-855-273-0468 or fill-in the form at this link.
Please see full Prescribing Information at:
https://gelclair.com/assets/Gelclair_PI_Decemeber_2021.pdf
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that top line results from the OnTarget study are forthcoming. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1 Oronsky B, et al. Transl Oncol. 2018;11(3):771-778.
2 Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020 Oct 7;39(1):210. doi: 10.1186/s13046-020-01715-7. PMID: 33028357; PMCID: PMC7542970
3 Jensen SB, Peterson DE. J Oral Pathol Med. 2014;43(2):81-90.
4 Nonzee NJ, et al. Cancer. 2008;113(6):1446-1452.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
Holy cow someone just scooped up 2,505,420 shares .0026 Weeeeeeeee
This is the real combo. We are going to .20 and higher today.
Awesome news! kaBOOOM
1.6m at .0025 fake ask or an idiot doesn't know how to trade.
Slowly but surely, we are going higher.
I Just reloaded 129,700 shares again. I will flip after hours.
04/15/24 03:00 PM ET Buy 36 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 200 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 100 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 700 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 200 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 700 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 1200 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 2549 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 1200 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 30000 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 200 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 615 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 700 JAGX Executed @ $0.107
04/15/24 03:00 PM ET Buy 1300 JAGX Executed @ $0.107
04/15/24 02:56 PM ET Buy 50000 JAGX Executed @ $0.1076
04/15/24 02:56 PM ET Buy 31461 JAGX Executed @ $0.1076
04/15/24 02:56 PM ET Buy 18539 JAGX Executed @ $0.1076
Not that high. Maybe .15 after hours. I flipped my 100k and loved the profit.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174228931
Good morning to all.
To me, it's an excellent stock to trade. I'll hold onto my free shares for the ride and flip a portion. I just bought 100,000 shares. I will buy more if it goes lower. With the gap just filled, I'm thinking it will move above $0.10 by next week. Last round, I flipped 238k near $0.13 cents.
04/12/24 04:00 PM ET Buy 50000 JAGX Executed @ $0.0903
04/12/24 03:56 PM ET Buy 23762 JAGX Executed @ $0.0917
04/12/24 03:56 PM ET Buy 14788 JAGX Executed @ $0.0917
04/12/24 03:56 PM ET Buy 11450 JAGX Executed @ $0.0917
Great action on Friday, it should continue gearing up higher next week. Ya have a Blessed Happy Weekend.
They missed a few mergers in the past, but hopefully, this time it's a done deal. From my perspective, everything aligns perfectly to seal the deal, and it's just a matter of time.
Have a blessed weekend.
It seems they're aiming to close the gap.
Thank you. This stock meets the criteria for my long-term investment consideration. My definition of long-term spans is at least a one-year time frame.
Thank you, and I'm grateful you guided me to AFFU.
The era of inexpensive shares below .008 seems to have ended. I anticipate profit-taking at around +60% to 100%. Once that subsides, this stock is poised to ascend further.
Agreed, I have great confidence in my investment here due to extensive research. It's only a matter of time before people realize the true potential of this opportunity. What makes this merger exceptional is the absence of reverse splits, elimination of debts, and no further dilution. Remarkably, the share structure has remained unchanged since April 2023 marking this one year without dilution. Such stability is exceedingly rare in the realm of OTC trading.
Moving up on the #3 breakout boards.
WOW! Never seen this before. Could someone be privy to something happening behind closed doors?
OMG! 6 million bids supporting at .0023
Someone just scooped up 922,650 shares .002
$PXMD +171%
Good morning, everyone! Indeed, exciting times lie ahead. Everything is falling into place for the common share exchange. It's no longer a question; it's just a matter of time. We're eagerly awaiting KOAN to file the Def 14A to approve increasing the company's shares from 200,000,000 to 2,000,000,000. This filing will occur on the 20th day after the definitive information statement is sent to the shareholders. Yes, we need this approval for the common shares exchange. YUP!
https://www.nasdaq.com/market-activity/stocks/koan/sec-filings
This is a required process orderly and regulated. They must say this. List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months.
At 5000/1, the put share price is $0.0015, resulting in $7.50 when multiplied by 5000. What will they do with $7.50 per share? Additionally, the stated outstanding shares at 85,390 is laughable. People need to remove their heads from the sand and think more logically.
Read the sticky if you are still confused.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174073191
.0015 bid supporting is my bid stands at 2 million shares. Upon reviewing the filings, I've opted to acquire additional shares for a long-term investment.
Awesome news. EMGE The annual Report indicated the entire o/s has changed in the control. This is a solid FACT. The countdown has begun...
https://www.otcmarkets.com/otcapi/company/financial-report/397344/content
The countdown for the share exchange has begun. I believe our moment is imminent; we could receive the share exchange announcement any day now. This is the moment I've eagerly waited for many months. I hope they opt for a 1-1 exchange; That would be truly life-changing for many long-term investors like us.
Absolutely, I have full confidence that under Morrison's leadership, our opportunity will come. Among the options available on the OTC market, EMGE stands out with its solid fundamentals and a robust management team.
With the company's outstanding shares half of ILST's, and ILST gaining 100% today, +400% in two days. There's no reason we can't move higher from $0.0006.